Table 2.

Descriptions of treatments following daclizumab (GMSR).

Drug given after daclizumab treatment (GMSR)	“Wash out period” in months mean (SD, median)	DMT had already been given previously to daclizumab (%)	DMT aborted within 6 months following daclizumab (%)
Teriflunomide	2.6 (5.1, 1.4)	5.0%	31.6%
Rituximab	3.0 (2.5, 3.4)	0.0%	40.0%
Ocrelizumab	4.0 (2.7, 3.8)	0.0%	2.9%
Natalizumab	1.2 (0.7, 1.1)	13.3%	0.0%
Glatiramer acetate	2.8 (3.1, 2.5)	11.1%	12.5%
Fingolimod	2.8 (2.9, 2.4)	12.5%	11.1%
Dimethyl fumarate	2.4 (1.0, 2.4)	10.0%	20.0%
Cladribine	3.9 (1.8, 3.0)	0%	11.8%